Regulating membrane lipid levels at the synapse by small-molecule inhibitors of monoacylglycerol lipase: new developments in therapeutic and PET imaging applications

Natasha L Grimsey; Juha R Savinainen; Bala Attili; Muneer Ahamed

doi:10.1016/j.drudis.2019.10.004

Regulating membrane lipid levels at the synapse by small-molecule inhibitors of monoacylglycerol lipase: new developments in therapeutic and PET imaging applications

Drug Discov Today. 2020 Feb;25(2):330-343. doi: 10.1016/j.drudis.2019.10.004. Epub 2019 Oct 14.

Authors

Natasha L Grimsey¹, Juha R Savinainen², Bala Attili³, Muneer Ahamed⁴

Affiliations

¹ Department of Pharmacology and Clinical Pharmacology, and Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, New Zealand.
² Institute of Biomedicine, Faculty of Health Sciences, The University of Eastern Finland, Finland.
³ Department of Radiology, The University of Cambridge, UK.
⁴ ARC Centre for Innovation in Biomedical Imaging Technology, Centre for Advanced Imaging, The University of Queensland, Australia. Electronic address: [email protected].

PMID: 31622747
DOI: 10.1016/j.drudis.2019.10.004

Abstract

Monoacylglycerol lipase (MAGL) is a major endocannabinoid hydrolyzing enzyme and can be regulated to control endogenous lipid levels in the brain. This review highlights the pharmacological roles and in vivo PET imaging of MAGL in brain.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Brain / diagnostic imaging
Brain / enzymology
Central Nervous System Diseases / drug therapy
Central Nervous System Diseases / enzymology
Enzyme Inhibitors / pharmacology*
Enzyme Inhibitors / therapeutic use
Humans
Membrane Lipids / metabolism*
Monoacylglycerol Lipases / antagonists & inhibitors*
Positron-Emission Tomography
Synapses / drug effects*
Synapses / metabolism

Substances

Enzyme Inhibitors
Membrane Lipids
Monoacylglycerol Lipases